New combo therapy targets rare bile duct cancer mutation in late-stage trial
NCT ID NCT07282262
First seen Dec 29, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a drug called ivosidenib, combined with lenvatinib or an immunotherapy, for people with advanced bile duct cancer that has a specific IDH1 gene change and has stopped responding to standard chemotherapy. The goal is to see if this targeted approach can shrink tumors or slow the cancer's growth. About 300 participants will receive the treatment and be monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Peking Union Medical College Hospital Outpatient Department
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.